Search results for "DIABETES MELLITUS"

showing 10 items of 2077 documents

Diabetes is not associated with COVID-19-related mortality in older institutionalized people

2021

Diabetes & Metabolism - Sous presse. Manuscrit accepte. Disponible en ligne depuis le mercredi 27 janvier 2021

2019-20 coronavirus outbreakPediatricsmedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)business.industryEndocrinology Diabetes and MetabolismSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)MEDLINE030209 endocrinology & metabolismGeneral Medicine030204 cardiovascular system & hematologymedicine.disease03 medical and health sciences0302 clinical medicineEndocrinologyDiabetes mellitusInternal MedicineMedicineLetters to the EditorbusinessDiabetes & Metabolism
researchProduct

Antidiabetic Drugs in NAFLD: The Accomplishment of Two Goals at Once?

2018

Non-Alcoholic Fatty Liver Disease (NAFLD) is the most common cause of chronic liver disease in Western countries, accounting for 20–30% of general population and reaching a prevalence of 55% in patients with type 2 diabetes mellitus (T2DM). Insulin resistance plays a key role in pathogenic mechanisms of NAFLD. Many drugs have been tested but no medications have yet been approved. Antidiabetic drugs could have a role in the progression reduction of the disease. The aim of this review is to summarize evidence on efficacy and safety of antidiabetic drugs in patients with NAFLD. Metformin, a biguanide, is the most frequently used drug in the treatment of T2DM. To date 15 randomized controlled t…

3003medicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentlcsh:Medicinelcsh:RS1-441Pharmaceutical Sciencehepatic cirrhosis030209 endocrinology & metabolismReviewChronic liver diseaseGastroenterologylcsh:Pharmacy and materia medica03 medical and health sciences0302 clinical medicineInsulin resistanceInternal medicineDiabetes mellitusDrug DiscoverymedicineBiguanidebusiness.industryLiraglutideInsulinlcsh:RFatty liverThiazolidinedionenutritional and metabolic diseasesnon-alcoholic fatty liver diseaseLiraglutidemedicine.diseaseMetforminMetforminHepatic cirrhosiMolecular Medicine030211 gastroenterology & hepatologyThiazolidinedionesnon-alcoholic steatohepatitisbusinessNon-alcoholic steatohepatitimedicine.drugPharmaceuticals (Basel, Switzerland)
researchProduct

Safety Evaluation of α-Lipoic Acid Supplementation: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Clinical Studies

2020

Alpha-lipoic acid (ALA) is a natural short-chain fatty acid that has attracted great attention in recent years as an antioxidant molecule. However, some concerns have been recently raised regarding its safety profile. To address the issue, we aimed to assess ALA safety profile through a systematic review of the literature and a meta-analysis of the available randomized placebo-controlled clinical studies. The literature search included EMBASE, PubMed Medline, SCOPUS, Google Scholar, and ISI Web of Science by Clarivate databases up to 15th August 2020. Data were pooled from 71 clinical studies, comprising 155 treatment arms, which included 4749 subjects with 2558 subjects treated with ALA an…

:Chemicals and Drugs::Pharmaceutical Preparations::Placebos [Medical Subject Headings]Physiologyα -lipoic acid ; thioctic acid ; dietary supplement ; safety ; meta-analysisClinical BiochemistryDisease030204 cardiovascular system & hematologyBiochemistrymeta-analysi:Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Antioxidants [Medical Subject Headings]Dietary supplementchemistry.chemical_compound0302 clinical medicinethioctic aciddietary supplement meta-analysis safety thioctic acid α-lipoic acid:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Evaluation Studies as Topic::Clinical Trials as Topic::Controlled Clinical Trials as Topic::Randomized Controlled Trials as Topic [Medical Subject Headings]α-lipoic acidLipoic acidSafety profile:Publication Type::Study Characteristics::Meta-Analysis [Medical Subject Headings]Suplementos dietéticosMeta-analysis:Technology and Food and Beverages::Food and Beverages::Food::Dietary Supplements [Medical Subject Headings]SafetysafetyAlpha-lipoic acidmedicine.medical_specialtyMEDLINEÁcido tióctico030209 endocrinology & metabolismPlacebo:Chemicals and Drugs::Organic Chemicals::Sulfur Compounds::Thiophenes::Thioctic Acid [Medical Subject Headings]Article:Health Care::Environment and Public Health::Public Health::Accidents::Accident Prevention::Safety [Medical Subject Headings]03 medical and health sciencesα‐lipoic acidThioctic acidInternal medicineDiabetes mellitusmedicineMetaanálisisAdverse effectSeguridad:Diseases::Cardiovascular Diseases [Medical Subject Headings]Molecular Biology:Chemicals and Drugs::Lipids::Fatty Acids::Fatty Acids Volatile [Medical Subject Headings]business.industryRevisión sistemáticalcsh:RM1-950Cell Biologymedicine.disease:Psychiatry and Psychology::Behavior and Behavior Mechanisms::Behavior::Habits::Food Habits::Smoking [Medical Subject Headings]meta-analysisMeta-analysislcsh:Therapeutics. Pharmacologychemistry:Diseases::Nervous System Diseases [Medical Subject Headings]dietary supplementMeta‐analysisbusinessAntioxidants
researchProduct

Patients' and physicians' preferences for type 2 diabetes mellitus treatments in Spain and Portugal: a discrete choice experiment.

2015

Objective: To assess Spanish and Portuguese patients' and physicians' preferences regarding type 2 diabetes mellitus (T2DM) treatments and the monthly willingness to pay (WTP) to gain benefits or avoid side effects. Methods: An observational, multicenter, exploratory study focused on routine clinical practice in Spain and Portugal. Physicians were recruited from multiple hospitals and outpatient clinics, while patients were recruited from eleven centers operating in the public health care system in different autonomous communities in Spain and Portugal. Preferences were measured via a discrete choice experiment by rating multiple T2DM medication attributes. Data were analyzed using the cond…

:Geographicals::Geographic Locations::Europe::Portugal [Medical Subject Headings]cardiovascular riskHbA1cendocrine system diseases:Analytical Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Diagnostic Techniques and Procedures::Physical Examination::Body Constitution::Body Weights and Measures::Body Mass Index [Medical Subject Headings]:Diseases::Nutritional and Metabolic Diseases::Metabolic Diseases::Glucose Metabolism Disorders::Hypoglycemia [Medical Subject Headings]:Disciplines and Occupations::Health Occupations::Medicine::Public Health [Medical Subject Headings]:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Probability::Risk::Risk Factors [Medical Subject Headings]:Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings]:Named Groups::Persons::Occupational Groups::Health Personnel::Physicians [Medical Subject Headings]HbA(1c)HbA:Diseases::Pathological Conditions Signs and Symptoms::Signs and Symptoms::Body Weight::Body Weight Changes::Weight Loss [Medical Subject Headings]:Diseases::Cardiovascular Diseases [Medical Subject Headings]preferences:Geographicals::Geographic Locations::Europe::Spain [Medical Subject Headings]diabetesnutritional and metabolic diseasesPeso corporalweightPérdida de peso:Health Care::Health Care Facilities Manpower and Services::Health Facilities::Ambulatory Care Facilities [Medical Subject Headings]Diabetes mellitus tipo 2:Diseases::Pathological Conditions Signs and Symptoms::Signs and Symptoms::Signs and Symptoms Digestive::Nausea [Medical Subject Headings]hypoglycemia:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Models Statistical::Logistic Models [Medical Subject Headings]:Diseases::Pathological Conditions Signs and Symptoms::Signs and Symptoms::Body Weight [Medical Subject Headings]:Diseases::Nutritional and Metabolic Diseases::Metabolic Diseases::Glucose Metabolism Disorders::Diabetes Mellitus::Diabetes Mellitus Type 2 [Medical Subject Headings]:Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Physiological Effects of Drugs::Hypoglycemic Agents [Medical Subject Headings]Enfermedades cardiovascularesHipoglucemiawillingness to pay:Check Tags [Medical Subject Headings]discrete choice model
researchProduct

Latvijas Universitātes Raksti. 755. sēj.

2010

:MEDICINE [Research Subject Categories]Iron deficiencyDzelzs deficīts2. tipa cukura diabētsVairogdziedzera vēzisUzmanības deficīta sindromsAerobās darbspējasEndoskopiska retrogrāda holangiopankreatogrāfijaMedicīniskās palīdzības pieejamībaPsoriāzeSkin precursor cellsBody massCitokīniType 2 diabetes mellitusKoagulāzes negatīvie stafilokoki
researchProduct

Grip Strength, Neurocognition, and Social Functioning in People WithType-2 Diabetes Mellitus, Major Depressive Disorder, Bipolar Disorder, and Schizo…

2020

[Background] Frailty is a common syndrome among older adults and patients with several comorbidities. Grip strength (GS) is a representative parameter of frailty because it is a valid indicator of current and long-term physical conditions in the general population and patients with severe mental illnesses (SMIs). Physical and cognitive capacities of people with SMIs are usually impaired; however, their relationship with frailty or social functioning have not been studied to date. The current study aimed to determine if GS is a valid predictor of changes in cognitive performance and social functioning in patients with type-2 diabetes mellitus and SMIs.

:Psychiatry and Psychology::Mental Disorders::Mood Disorders::Affective Disorders Psychotic::Bipolar Disorder [Medical Subject Headings]:Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings]0302 clinical medicine:Psychiatry and Psychology::Mental Disorders::Mood Disorders::Depressive Disorder::Depressive Disorder Major [Medical Subject Headings]Social functioningPsychology030212 general & internal medicineType-2 diabetes mellitusCognitive performancecognitive performanceGeneral PsychologyOriginal Research:Persons::Persons::Age Groups::Adult::Aged [Medical Subject Headings]:Persons::Persons::Patients::Outpatients [Medical Subject Headings]education.field_of_studyFrailtyCognition:Disciplines and Occupations::Natural Science Disciplines::Physics::Electronics [Medical Subject Headings]Type-2 diabetesmellitusFragilidadDiabetes mellitus tipo 2SchizophreniaTrastornos mentalesMajor depressive disorder:Diseases::Nutritional and Metabolic Diseases::Metabolic Diseases::Glucose Metabolism Disorders::Diabetes Mellitus::Diabetes Mellitus Type 2 [Medical Subject Headings]PsychologyClinical psychologyFuerza de la manoPopulationlcsh:BF1-990frailty03 medical and health sciencessevere mental illness:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cohort Studies::Longitudinal Studies::Follow-Up Studies [Medical Subject Headings]Severe mental illnessmedicine:Psychiatry and Psychology::Mental Disorders::Schizophrenia and Disorders with Psychotic Features::Schizophrenia [Medical Subject Headings]Effects of sleep deprivation on cognitive performanceBipolar disordereducation:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Regression Analysis [Medical Subject Headings]:Psychiatry and Psychology::Psychological Phenomena and Processes::Mental Processes::Cognition [Medical Subject Headings]:Analytical Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Diagnostic Techniques and Procedures::Physical Examination::Muscle Strength::Hand Strength [Medical Subject Headings]Type 2 Diabetes Mellitustype-2 diabetes mellitusmedicine.diseasesocial functioninglcsh:PsychologyGrip strengthgrip strengthInteracción socialNeurocognitive:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Analysis of Variance [Medical Subject Headings]030217 neurology & neurosurgeryFrontiers in Psychology
researchProduct

Cardiovascular and Renal Outcomes of Renin–Angiotensin System Blockade in Adult Patients with Diabetes Mellitus: A Systematic Review with Network Met…

2016

Background Medications aimed at inhibiting the renin–angiotensin system (RAS) have been used extensively for preventing cardiovascular and renal complications in patients with diabetes, but data that compare their clinical effectiveness are limited. We aimed to compare the effects of classes of RAS blockers on cardiovascular and renal outcomes in adults with diabetes. Methods and Findings Eligible trials were identified by electronic searches in PubMed/MEDLINE and the Cochrane Database of Systematic Reviews (1 January 2004 to 17 July 2014). Interventions of interest were angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), and direct renin (DR) inhibitors. T…

ACE inhibitorsMyocardial InfarctionAngiotensin-Converting Enzyme Inhibitors030204 cardiovascular system & hematologyACE inhibitor therapyBiochemistryRenin-Angiotensin SystemAnginachemistry.chemical_compoundEndocrinologyMathematical and Statistical Techniques0302 clinical medicineReninMedicine and Health SciencesSecondary Prevention030212 general & internal medicineMyocardial infarctionDiureticsStrokePharmaceuticsRDrugsEnzyme inhibitorsCardiovascular therapyGeneral Medicine3. Good healthHospitalizationStrokeNephrologyCardiovascular DiseasesPhysical SciencesCardiologyMedicineDrug therapyStatistics (Mathematics)Research Articlemedicine.drugAdultmedicine.medical_specialtyEndocrine DisordersCardiologyResearch and Analysis MethodsAngina PectorisDiabetes ComplicationsAngiotensin Receptor Antagonists03 medical and health sciencesDiabetes mellitusInternal medicineRenal DiseasesDiabetes MellitusmedicineHumansStatistical MethodsRenal Insufficiency ChronicPharmacologyHeart FailureCreatinineBiology and life sciencesbusiness.industryOdds ratiomedicine.diseasechemistryMetabolic DisordersHeart failuresistema cardiovascularACE inhibitorEnzymologyKidney Failure ChronicbusinessMathematicsMeta-AnalysisPLOS Medicine
researchProduct

Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease.

2022

Funder: European Commission

ALTtype 2 diabetes mellitusROC receiving operator characteristicaspartate aminotransferaseHSDLDL low-density lipoproteinUHPLC ultrahigh-performance liquid chromatographyROCHCCNon-alcoholic steatohepatitisGCPCANASHGastroenterology2-HB 2-hydroxybutanoic acid; 3-HB 3-hydroxybutanoic acid; ALT alanine aminotransferase; AST aspartate aminotransferase; CE cholesterol ester; Cer ceramide; FFA free fatty acid; FLIP Fatty Liver Inhibition of Progression; Fibrosis; GC gas chromatography; HCC hepatocellular carcinoma; HSD honest significant difference; LC lipid cluster; LDL low-density lipoprotein; LM lipid and metabolite; LMC lipid metabolite and clinical variable; LPC lysophosphatidylcholine; Lipidomics; Mass spectrometry; Metabolomics; NAFL non-alcoholic fatty liver; NAFLD non-alcoholic fatty liver disease; NAS NASH activity score; NASH non-alcoholic steatohepatitis; NIDDK NASH-CRN National Institute of Digestive Diseases and Kidney NASH Clinical Research Network; NRR non-rejection rate; Non-alcoholic steatohepatitis; PC(O) ether PC; PC phosphatidylcholine; PCA principal component analysis; PE phosphatidylethanolamine; QTOFMS quadrupole-time-of-flight mass spectrometry; ROC receiving operator characteristic; SAF steatosis activity and fibrosis; SM sphingomyelin; T2DM type 2 diabetes mellitus; TG triacylglycerol; UHPLC ultrahigh-performance liquid chromatographySAFSAF steatosis activity and fibrosisLM lipid and metabolitehonest significant differenceHSD honest significant differenceTG triacylglycerolnon-rejection ratecholesterol esterPCPEGC gas chromatographyfree fatty acidFLIPNASH non-alcoholic steatohepatitisNIDDK NASH-CRN National Institute of Digestive Diseases and Kidney NASH Clinical Research NetworkBIOMARKERST2DMPE phosphatidylethanolamineLDLlipidNAFLDFFA free fatty acid2-HBMetabolomicsNAFL non-alcoholic fatty liverLMCphosphatidylcholineScience & TechnologySM sphingomyelinGastroenterology & HepatologyMass spectrometryactivitynutritional and metabolic diseasesT2DM type 2 diabetes mellitusACIDSreceiving operator characteristicdigestive system diseasesquadrupole-time-of-flight mass spectrometryLC lipid clusterlow-density lipoproteinNAS2-HB 2-hydroxybutanoic acidNAS NASH activity scoreQTOFMSether PCNRRSCORING SYSTEMprincipal component analysisgas chromatographyLC2-hydroxybutanoic acidPROGRESSIONAST aspartate aminotransferaseLMPC phosphatidylcholinePC(O)MARKERSUHPLCsteatosisTOOLImmunology and AllergyINSULIN-RESISTANCECerSMFatty Liver Inhibition of Progressionhepatocellular carcinoma2-HB 2-hydroxybutanoic acid NIDDK NASH-CRN National Institute of Digestive Diseases and Kidney NASH Clinical Research Network NRR non-rejection rate Non-alcoholic steatohepatitis PC(O) ether PC PC phosphatidylcholine PCA principal component analysis PE phosphatidylethanolamine QTOFMS quadrupole-time-of-flight mass spectrometry ROC receiving operator characteristic SAF steatosis activity and fibrosis SM T2DM type 2 diabetes mellitus TG triacylglycerol UHPLC ultrahigh-performance liquid chromatographyultrahigh-performance liquid chromatographyCELPC3-HBNAFLnon-alcoholic fatty liverTGtriacylglycerolNRR non-rejection rateLife Sciences & BiomedicineNAFLD non-alcoholic fatty liver diseaseFLIP Fatty Liver Inhibition of Progressionalanine aminotransferasemetaboliteCer ceramideCE cholesterol estersphingomyelinlysophosphatidylcholineand fibrosisALT alanine aminotransferaseInternal MedicineceramideNational Institute of Digestive Diseases and Kidney NASH Clinical Research NetworkAST3-HB 3-hydroxybutanoic acidQTOFMS quadrupole-time-of-flight mass spectrometryPCA principal component analysisLPC lysophosphatidylcholineHepatologynon-alcoholic fatty liver diseaseand clinical variablePC(O) ether PC3-hydroxybutanoic acidFibrosisNASH activity scoreNIDDK NASH-CRNlipid clusterlipid and metabolitephosphatidylethanolamineLipidomicsLMC lipid metabolite and clinical variableFFAHCC hepatocellular carcinomaJHEP reports : innovation in hepatology
researchProduct

Metformin influences drug sensitivity in pancreatic cancer cells

2018

Abstract Pancreatic ductal adenocarcinoma (PDAC) is an aggressive, highly metastatic malignancy and accounts for 85% of pancreatic cancers. PDAC patients have poor prognosis with a five-year survival of only 5–10% after diagnosis and treatment. Pancreatic cancer has been associated with type II diabetes as the frequency of recently diagnosed diabetics that develop pancreatic cancer within a 10-year period of initial diagnosis of diabetes in increased in comparison to non-diabetic patients. Metformin is a very frequently prescribed drug used to treat type II diabetes. Metformin acts in part by stimulating AMP-kinase (AMPK) and results in the suppression of mTORC1 activity and the induction o…

AMPK0301 basic medicineCancer Researchendocrine system diseases03 medical and health sciencesPancreatic cancerGeneticsMedicineAnimalsHumansDoxorubicinDrug InteractionsRapamycinSignal transduction inhibitormTORC1Molecular BiologyCisplatinSirolimusAnimalbusiness.industryPancreatic NeoplasmCancermedicine.diseaseGemcitabineMetforminMetforminPancreatic Neoplasms030104 developmental biologyDrug InteractionDocetaxelDiabetes Mellitus Type 2SirolimusCancer researchMolecular MedicinebusinessHumanmedicine.drugCarcinoma Pancreatic DuctalSignal Transduction
researchProduct

Activation of AMPK by medicinal plants and natural products: Its role in type 2 diabetes mellitus

2019

Type-2 Diabetes (T2D) is a metabolic disease characterized by permanent hyperglycemia, whose development can be prevented or delayed by using therapeutic agents and implementing lifestyle changes. Some therapeutic alternatives include regulation of glycemia through modulation of different mediators and enzymes, such as AMP-activated protein kinase (AMPK), a highly relevant cellular energy sensor for metabolic homeostasis regulation, with particular relevance in the modulation of liver and muscle insulin sensitivity. This makes it a potential therapeutic target for antidiabetic drugs. In fact, some of them are standard drugs used for treatment of T2D, such as biguanides and thiazoli-dindione…

AMPKCIENCIAS MÉDICAS Y DE LA SALUDBiguanidesAMP-Activated Protein KinasesPharmacologyResveratrolCarbohydrate metabolismNATURAL PRODUCTS03 medical and health scienceschemistry.chemical_compound0302 clinical medicineBerberineDiabetes mellitusDrug DiscoveryHumansHypoglycemic AgentsMedicineTYPE 2 DIABETES MELLITUSProtein kinase A030304 developmental biologyPharmacologychemistry.chemical_classificationBiological Products0303 health sciencesPlants Medicinalbusiness.industryType 2 Diabetes MellitusAMPKGeneral MedicineBioquímica y Biología Molecularmedicine.diseaseANTIDIABETIC DRUGSMedicina BásicaGlucoseEnzymeDiabetes Mellitus Type 2chemistry030220 oncology & carcinogenesisThiazolidinedionesbusinessMEDICINAL PLANTS
researchProduct